Zalospirone

Zalospirone
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
Elimination half-life1-4 hours
Identifiers
  • (3aα,4α,4aβ,6aβ,7α,7aα)-Hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H29N5O2
Molar mass419.529 g·mol−1
3D model (JSmol)
  • O=C1N(C(=O)[C@@H]4[C@H]1[C@@H]2\C=C/[C@H]4[C@H]3\C=C/[C@@H]23)CCCCN6CCN(c5ncccn5)CC6
  • InChI=1S/C24H29N5O2/c30-22-20-18-6-7-19(17-5-4-16(17)18)21(20)23(31)29(22)11-2-1-10-27-12-14-28(15-13-27)24-25-8-3-9-26-24/h3-9,16-21H,1-2,10-15H2/t16-,17+,18-,19+,20-,21+
  • Key:AERLHOTUXIJQFV-RCPZPFRWSA-N
  (verify)

Zalospirone (WY-47,846) is a selective 5-HT1A partial agonist of the azapirone chemical class.[1][2] It was found to be effective in the treatment of anxiety and depression in clinical trials, but a high proportion of subjects dropped out due to side effects and development was subsequently never completed.[3]

  1. ^ Gleeson S, Barrett JE (October 1990). "5-HT1A agonist effects on punished responding of squirrel monkeys". Pharmacology, Biochemistry, and Behavior. 37 (2): 335–7. doi:10.1016/0091-3057(90)90344-H. PMID 1981937. S2CID 23488390.
  2. ^ Singh A, Lucki I (April 1993). "Antidepressant-like activity of compounds with varying efficacy at 5-HT1A receptors". Neuropharmacology. 32 (4): 331–40. doi:10.1016/0028-3908(93)90153-T. PMID 8497336. S2CID 38611829.
  3. ^ Rickels K, Derivan A, Kunz N, Pallay A, Schweizer E (June 1996). "Zalospirone in major depression: a placebo-controlled multicenter study". Journal of Clinical Psychopharmacology. 16 (3): 212–7. doi:10.1097/00004714-199606000-00004. PMID 8784652.